Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04325529 · ClinicalTrials.gov registry record
Pharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Study 1.2 (Stress Manipulation)
A clinical trial of Major Depression in Remission, sponsored by Mclean Hospital.
- Active
- Registry status
- 148
- Enrollment target
- 1
- Study location
NCT04325529 is a study of Major Depression in Remission that is active but no longer recruiting, run by Mclean Hospital. The registered enrollment target is 148 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04325529, a study of Major Depression in Remission, is active but no longer recruiting, sponsored by Mclean Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- 148 participants
- Enrollment target
- 1
- Study location
Study Summary
This study investigates how remitted individuals with past major depressive disorder (MDD) make approach-avoidance decisions and which brain regions are implicated in such decisions. Information collected through MRI and behavioral tasks will be used to predict depressive symptoms in the future.
Conditions Studied
Interventions
- DEVICE Aversive stimuli
Study Locations (1)
Massachusetts
- McLean Hospital - Belmont
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2021-01-19 |
| Est. Completion | 2026-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04325529
The ClinicalTrials.gov registry entry for NCT04325529 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 148 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mclean Hospital, which has 140 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Major Depression in Remission appearing as the primary indexed condition, and to 1 intervention - of which Aversive stimuli is the first listed.
NCT04325529 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04325529 about?
NCT04325529 is a clinical study titled "Pharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Study 1.2 (Stress Manipulation)". This study investigates how remitted individuals with past major depressive disorder (MDD) make approach-avoidance decisions and which brain regions are implicated in such decisions. Information collected through MRI and behavioral tasks will be used to predict depressive symptoms in the future.
What is the current status of trial NCT04325529?
This trial is currently active not recruiting. The enrollment target is 148 participants. The study started on 2021-01-19. Estimated completion is 2026-06-30.
What conditions does trial NCT04325529 study?
This clinical trial studies the following conditions: Major Depression in Remission.
What interventions are being tested in trial NCT04325529?
The interventions under investigation include: Aversive stimuli (DEVICE).
Who is sponsoring clinical trial NCT04325529?
This trial is sponsored by Mclean Hospital, which has 140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04325529 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.